Technical Analysis for MDNA - Medicenna Therapeutics Corp.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | -1.80% | |
| Calm After Storm | Range Contraction | -1.80% | |
| NR7 | Range Contraction | -1.80% | |
| Wide Bands | Range Expansion | -1.80% | |
| Down 3 Days in a Row | Weakness | -1.80% | |
| Down 4 Days in a Row | Weakness | -1.80% | |
| Fell Below 20 DMA | Bearish | -5.20% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | -5.20% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -5.20% | |
| Wide Bands | Range Expansion | -5.20% |
| Alert | Time |
|---|---|
| Possible NR7 | about 1 hour ago |
| Fell Below Previous Day's Low | about 3 hours ago |
| Down 1% | about 3 hours ago |
| Up 2% | about 5 hours ago |
| Up 1% | about 5 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 2024-02-12
Medicenna Therapeutics Corp. Description
Medicenna Therapeutics Corp, formerly A2 Acquisition Corp, is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing engineered versions of Interleukin (IL)-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines (ECs). The Company focuses on commercialization EC and Superkines for the treatment of cancer. The Company's IL4 EC is a drug that targets the Bulk Tumor, Cancer Stem Cells and Immunosuppressive Cells of the Tumor Micro-environment. MDNA55 is the Company's lead product. MDNA55 is being studied in clinical trials for treatment of CNS cancers. The Company's MDNA56 and MDNA57 are its IL-4 carrying a human cell killing payload. MDNA56 is being developed for the treatment of hematopoietic cancers expressing the Type 1 IL-4R, whereas MDNA57 is intended to selectively target solid tumors and non-malignant cells of the tumor micro-environment expressing the Type 2 IL-4R.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinic Drug Cancer Medical Specialties Clinical Trial Oncology Clinical Medicine Cancers Tumor Immunotherapy Stem Cells Treatment Of Cancer Cancer Immunotherapy Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.1 |
| 52 Week Low | 0.215 |
| Average Volume | 172,596 |
| 200-Day Moving Average | 0.691 |
| 50-Day Moving Average | 1.372 |
| 20-Day Moving Average | 1.747 |
| 10-Day Moving Average | 1.781 |
| Average True Range | 0.191 |
| RSI (14) | 51.22 |
| ADX | 32.27 |
| +DI | 24.673 |
| -DI | 20.993 |
| Chandelier Exit (Long, 3 ATRs) | 1.527 |
| Chandelier Exit (Short, 3 ATRs) | 1.873 |
| Upper Bollinger Bands | 2.051 |
| Lower Bollinger Band | 1.444 |
| Percent B (%b) | 0.37 |
| BandWidth | 34.751 |
| MACD Line | 0.122 |
| MACD Signal Line | 0.156 |
| MACD Histogram | -0.0341 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.820 | ||||
| Resistance 3 (R3) | 1.837 | 1.803 | 1.795 | ||
| Resistance 2 (R2) | 1.803 | 1.765 | 1.795 | 1.787 | |
| Resistance 1 (R1) | 1.737 | 1.742 | 1.720 | 1.720 | 1.778 |
| Pivot Point | 1.703 | 1.703 | 1.695 | 1.695 | 1.703 |
| Support 1 (S1) | 1.637 | 1.665 | 1.620 | 1.620 | 1.562 |
| Support 2 (S2) | 1.603 | 1.642 | 1.595 | 1.553 | |
| Support 3 (S3) | 1.537 | 1.603 | 1.545 | ||
| Support 4 (S4) | 1.520 |
